CellaVision AB (publ)
CEVI
Rank in Stocks
#12236
CellaVision AB (publ), a Swedish enterprise established in 1994 and based in... CellaVision AB (publ), a Swedish enterprise established in 1994 and based in Lund, specializes in crafting and distributing advanced digital systems for analyzing blood and other bodily fluids within the healthcare industry. The company serves a global market, with operations extending across Sweden, the wider European continent, the Middle East, Africa, the Americas, and the Asia Pacific region. Their core product line includes automated digital imaging devices such as the CellaVision DM1200 and DM9600, engineered to automatically capture detailed digital images of cells from blood smears and fluid preparations. Additionally, they offer the CellaVision DC-1 analyzer. Beyond hardware, CellaVision provides a suite of specialized software applications. The CellaVision Peripheral Blood Application streamlines and standardizes the morphological assessment of peripheral blood smears, while the CellaVision Advanced RBC Application facilitates a thorough examination of red blood cell morphology. For other body fluids, the CellaVision Body Fluid Application automates and standardizes their morphological evaluation. To enhance operational flexibility, the CellaVision Remote Review Software allows for the review of digital smears without geographical restrictions. Furthermore, the company delivers tools designed for laboratory management and educational purposes. The CellaVision Server Software integrates workflows across single or multiple testing facilities into a cohesive system. The CellaVision Dashboard provides an instant, visual summary of analyzer and reviewer performance data. The cloud-based CellaVision Proficiency Software assists laboratory managers in evaluating, tracking, and developing staff competency in cell morphology. For training and reference, the CellaVision CellAtlas features concise educational modules alongside a comprehensive cell image library. CellaVision also caters to the animal health sector with CellaVision VET, offering digital microscopy solutions for veterinary hematology. These innovative solutions are primarily supplied to hospitals and commercial laboratories worldwide.
Share Price
$20.41
Last synced: 2026-11-09
Market Cap
$486.70M
Change (1 day)
1.43%
Change (1 year)
20.18%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade CellaVision AB (publ) (CEVI)
Category
Healthcare
EPS for CellaVision AB (publ) (CEVI)
EPS as of September 2026 TTM: $0.58
According to CellaVision AB (publ)'s latest financial reports, its current EPS (TTM) is $0.58. At the end of 2025 the company had an EPS of $0.70, an increase over its 2024 EPS of $0.53.
EPS history for CellaVision AB (publ) from 2007 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $0.58 | -16.66% |
| 2025 | $0.70 | 30.08% |
| 2024 | $0.53 | -1.16% |
| 2023 | $0.54 | 13.77% |
| 2022 | $0.48 | -18.00% |
| 2021 | $0.58 | 27.83% |
| 2020 | $0.45 | 1.84% |
| 2019 | $0.45 | 7.01% |
| 2018 | $0.42 | 16.61% |
| 2017 | $0.36 | 29.24% |
| 2016 | $0.28 | 4.98% |
| 2015 | $0.26 | 55.65% |
| 2014 | $0.17 | 37.82% |
| 2013 | $0.12 | 195.66% |
| 2012 | $0.04 | -53.16% |
| 2011 | $0.09 | -63.07% |
| 2010 | $0.24 | 47.54% |
| 2009 | $0.16 | 21.34% |
| 2008 | $0.13 | 683.63% |
| 2007 | $0.02 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $2.70 | 362.80% |
US
|
|
| $4.09 | 601.06% |
IE
|
|
| $9.45 | 1,519.81% |
US
|
|
| $2.37 | 306.24% |
US
|
|
| $1.77 | 203.39% |
US
|
Questions about CellaVision AB (publ)'s earnings per share (EPS)
What is CellaVision AB (publ)'s earnings per share (EPS)?
CellaVision AB (publ)'s earnings per share (EPS) over the last twelve months is $0.58, as of Sep 2026.
What was CellaVision AB (publ)'s earnings per share (EPS) in 2025?
In 2025, CellaVision AB (publ)'s earnings per share (EPS) was $0.70, 32.08% more than in 2024 ($0.53).
How has CellaVision AB (publ)'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, CellaVision AB (publ)'s earnings per share (EPS) went from $0.45 to $0.70, an average growth of 9.24% a year.
How does CellaVision AB (publ)'s earnings per share (EPS) compare with similar companies?
CellaVision AB (publ)'s earnings per share (EPS) ($0.58) is lower than that of all 5 similar companies listed above. The highest among them is Stryker Corporation, with $9.45.